MAP2K7 and hepatocellular carcinoma: Sorafenib, a dual-action inhibitor that targets the RAF/MEK/ERK pathway, is used for clinical chemotherapy of HCC and significantly prolongs patient survival (Llovet et al., 2008), while 5-FU is a chemotherapy drug used to treat a variety of solid tumors, including HCC, with promising effects (Kasai et al., 2012).